A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Inclusion Criteria:

• Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years
• Treatment with Xeomin® and BOTOX® for at least 2 years each.

Exclusion Criteria:

• Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission
• Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.